Burnett Patrick sold $25K of ARQT

Burnett Patrick (See Remarks) sold 955 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $26.12 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Burnett Patrick
Published Aug 6, 2026, 1:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not include new guidance, trial results, regulatory actions, or deal terms.

02

Market read

A small, scheduled insider sale is unlikely to drive fundamentals, but it can marginally influence sentiment around ARQT.

03

What to watch

Traders may overreact to insider sales; the key is whether there is a pattern of repeated sales outside scheduled plans, which is not evidenced here.

Relevance 2/10Novelty 2/10Timing: filed Aug 5, transaction dated Aug 3 (insider sale disclosure)

Background

The article is an SEC Form 4 insider transaction report for Arcutis Biotherapeutics, Inc.

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Arcutis Biotherapeutics insider Burnett Patrick sold 955 shares in an open-market transaction on Aug 3 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless follow-on selling appears.

Evidence & confidence

The filing is a Form 4 open-market sale with a pre-arranged 10b5-1 plan; no new company-specific operational or financial information is provided.

Market effects

Minimal; insider sale does not signal sector-wide change.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect liquidity needs rather than bearish expectations.

Key entities

  • Arcutis Biotherapeutics, Inc.

    US-listed biotherapeutics company subject of the Form 4 insider sale disclosure.

  • Burnett Patrick

    Officer who sold 955 shares on Aug 3 at $26.1168/share under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARQTHighAI 8/10

Arcutis reports trial data on infant eczema treatment candidate

Arcutis Biotherapeutics (ARQT) presented INTEGUMENT-INFANT trial data for ZORYVE cream 0.05% in treating infant atopic dermatitis. The study showed no serious adverse events, with 66.7% of infants reporting itch improvement within 4 hours. The cream is approved for children 2-5 years and is under FDA review for infants 3-24 months, with a decision expected by February 23, 2027.

$ARQTMed

Arcutis (ARQT) Q3 2026 Earnings Call Transcript

Arcutis Biotherapeutics (ARQT) reported Q3 2026 revenue of $143.9M, up 45% YoY, driven by ZORYVE franchise growth. Full-year revenue guidance raised to $535M-$545M. Net income was $8.8M, with cash and securities at $259.8M. The company plans to invest in commercial initiatives for 2027 growth, focusing on dermatology and primary care.

$ARQTMedAI 8/10

TD Cowen raises Arcutis stock price target on Zoryve momentum

TD Cowen raised its price target for Arcutis Biotherapeutics (ARQT) to $40 from $35, citing strong Zoryve sales of $144M and raised 2026 guidance. Revenue grew 11% quarter-over-quarter and 45% year-over-year, with a 91% gross profit margin. The stock trades near its 52-week high at $34.05. Arcutis reported Q3 2026 revenue of $143.9M, beating estimates, but missed profit expectations.